Dualyx is heading towards the clinic with its regulatory T cells (Tregs) candidates, armed with €40m and the backing of several top-tier healthcare investors.
Investors Impressed With Dualyx Tregs Plans
Belgian Biotech Raises €40m
The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001, which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."
